Welcome to our dedicated page for Pharmagreen Biotech news (Ticker: PHBI), a resource for investors and traders seeking the latest updates and insights on Pharmagreen Biotech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pharmagreen Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pharmagreen Biotech's position in the market.
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) has successfully exited Chapter 11 bankruptcy proceedings, initiated voluntarily on August 11, 2020. The company’s exit was confirmed following a lifted stay order by a U.S. District Judge on October 9, 2020, regarding EMA Financial LLC’s action. CEO Peter Wojcik stated the company is now focused on advancing its business plans. Pharmagreen specializes in developing tissue-cultured hemp plantlets, offering a proprietary process for producing genetically uniform, disease-free plantlets with high cannabinoid content.